With regard to the compound NFX91 (a product developed by the Neurofix team), for the treatment of sleep disturbances, it is possible to indicate that approximately 58% of adults in Western countries suffer from insomnia for two or more nights a week.
Approximately 95% of patients with insomnia receive medication, and psychotherapies (for example, hypnosis) and natural
treatments (plants) are often used with a lower frequency. Among the drugs most commonly used to treat insomnia are
benzodiazepines (Valium, Ambion, Imobane, Lunesta), antihistamines (Benadryl, Restavit), antidepressants (Elavil, Deptran, Avanza), which in part justify the adverse effects of Said drugs. The melatonin analogues have not worked well, which has reduced the chances of treatments without adverse effects until now.
The NFX91 is, like all other Neurofix molecules, a "First-in-Class" focused directly on the treatment of insomnia.
Since its molecular structure is very similar to that of the natural compound, it should be expected that it will not give rise to any serious side effects. It is hoped that the investigation that is being carried out will allow to apply for a patent for a family of compounds focused on the treatment of sleep disorders.
NFX91. Neurofix has started an R & D program in the field of sleep disorders.
The project is based on research into the mechanisms of action that underlie the effect of oleamide derivatives,
a natural lipid involved in the onset of the process that disconnects a waking brain to start the sleep period.
A synthetic derivative of oleamide has been designed rationally and its efficacy in animal models will be studied.
It is expected to patent one or several molecules (Markush formula) in a period of less than 5 years. Subsequently,
it would proceed to the beginning of its pharmaceutical development (preclinical and clinical regulatory).